Human B-cell receptor recognizing conserved influenza epitopes (HA, NP, and M1)

The Human B-cell receptor (BCR) and its associated antibodies that recognize conserved linear epitopes on influenza proteins—specifically Hemagglutinin (HA), Nucleoprotein (NP), and Matrix protein 1 (M1)—are central to the development of universal influenza vaccines (Atsmon et al., 2012, Science Translational Medicine). While traditional vaccines target the rapidly mutating head of the HA protein, these BCRs target stalk regions or internal proteins that remain stable across diverse influenza strains and subtypes (Corti et al., 2011, Science). HA stalk-specific antibodies primarily function by inhibiting the pH-dependent membrane fusion required for viral entry into host cells (Dreyfus et al., 2012, Science). In contrast, antibodies targeting internal proteins like NP and M1 typically provide protection through non-neutralizing mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), which eliminate infected cells (Carragher et al., 2008, J Virol). By focusing the immune response on these invariant regions, therapeutic interventions like the M-001 vaccine aim to provide broad, universal protection against seasonal drift and potential pandemic shifts (Gottlieb et al., 2020, Lancet Infectious Diseases).

Other names

Broadly neutralizing influenza antibodiesUniversal influenza vaccine targetsHA-NP-M1 cross-reactive antibodiesConserved influenza epitope-specific B-cell receptorsStalk-specific influenza antibodies

Vaccine-mediated stimulation of B-cells to produce antibodies against conserved viral regions; Neutralization of viral fusion and Fc-mediated clearance of infected cells (Atsmon et al., 2012; Carragher et al., 2008).